In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Similarly, it was thought that intravenous immunoglobulin (IVIG)—holding multiple immunomodulatory effects—would provide clinically favorable results, but recent studies suggest otherwise. Still, the ...

Though the quality of evidence was low, combination rituximab and IVIG therapy may be a viable treatment option for patients with refractory autoimmune diseases. The combination of rituximab (RTX) and ...

Aim: To report on the efficacy and safety of elective switching from intravenously (IV) to subcutaneously (SC) administered Infliximab (IFX) in patients with immune mediated diseases. Methods: ...